Amanta Healthcare IPO GMP

September 10, 2025 Written By Mihir Gohel, Reviewed and Fact Checked by Harpal Parmar

The Amanta Healthcare IPO is scheduled to open for subscription from September 1 to September 3, 2025, with a price band between ₹120 and ₹126 per share. Amanta Healthcare specializes in the development, manufacturing, and marketing of sterile liquid pharmaceutical products, including parenteral solutions using advanced aseptic technologies. The company operates a WHO-GMP certified manufacturing facility and serves both domestic and international markets with products registered in 19 countries. The Amanta Healthcare IPO offers investors exposure to a leading player in the growing sterile injectables segment.

₹10

Latest IPO GMP

Last updated on 08 Sep 2025 12.47

₹126

IPO Offer Price

*cut off price

₹135.00

Listing Price

Listing Date 09/09/2025

Expert Opinions

The Amanta Healthcare IPO has generated cautious optimism among investors, reflecting interest in the growing pharmaceuticals sector but moderated by current industry headwinds. The company’s strengths include a robust portfolio of sterile liquid injectables, widespread regulatory approvals, and a WHO-GMP certified facility, supporting both domestic growth and international market penetration. Risks involve relatively thin profit margins, sector-specific regulatory scrutiny, and a debt-heavy capital structure.

The valuation for FY 2025 reveals the Amanta Healthcare IPO posted a Return on Net Worth (RONW) of 10.89, Return on Equity (ROE) of 12.42% and a Net Asset Value (NAV) of ₹33.43, suggesting reasonable but not aggressive capital efficiency. For long-term investors, the IPO offers exposure to the critical care and sterile drugs segments, though patience will be needed as the business navigates evolving regulations and market competitiveness.

Investor Considerations

The Amanta Healthcare IPO presents a company with stable fundamentals, reporting revenue of over ₹270 crore and profit after tax improving in FY 2025. Sector outlook remains positive as demand for sterile injectable pharmaceuticals continues to grow, supported by advancing healthcare infrastructure and regulatory tailwinds. The Amanta Healthcare IPO’s valuation shows ROCE at 13.72%, EBITDA margin of 22.11%, and a Debt/Equity ratio of 2.02, indicating healthy operational efficiency but a leveraged balance sheet.

Growth prospects are supported by global expansion and product portfolio diversification. Key risks include regulatory changes, pricing controls, and margin volatility from raw material costs. Long-term investors may benefit from sector growth and company expansion, while short-term investors should consider liquidity and sector-related risks before committing.